Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Business & Industry
- Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy
- Amgen and MBC Biolabs announce winners of the Amgen Golden Ticket
- Pfizer to organize for future growth
- XANTUS programme confirms low bleeding and low stroke rate with Xarelto® in 11,121 prospectively investigated patients with atrial fibrillation
- Bayer expands strategic alliance with Broad Institute of MIT and Harvard
Research & Development
- The immune system: T cells are built for speed
- Bioengineers create pathway to personalized medicine
- Short-term improved vascular function after consuming red raspberries
- Human clinical trial reveals verapamil as an effective type 1 diabetes therapy
- Researchers develop a new method for turning skin cells into pluripotent stem cells
- Data-sharing website may speed the response to new illegal drugs
- New small molecules pave the way for treating autoinflammatory disease
Conferences & Events
- SMi presents the 13th annual industry leading conference: Cold Chain Distribution
- Orphan Drugs and Rare Diseases Conference 2018
- Immuno-Oncology Conference 2018
- Ophthalmic Drugs Conference 2018
- SMi presents the launch of Cell & Gene Therapy 2018
- SMi presents the 9th Conference on Biosimilars & Biobetters
- SMi presents the 13th Conference on ADMET
Regulatory Affairs
- FDA warns of imposters sending consumers fake warning letters
- FDA takes steps to encourage more informative labeling on prescription drug and biological products' indications and usage
- FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy
- FDA takes steps to foster greater efficiency in biosimilar development by reconsidering draft guidance on evaluating analytical studies
- FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales
- FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment
- FDA takes new steps to advance digital health, opening docket to solicit feedback on software products